Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients

Bone Marrow Transplant. 2024 Jan;59(1):128-130. doi: 10.1038/s41409-023-02119-9. Epub 2023 Oct 10.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Bortezomib / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Melphalan / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Pyrazines / therapeutic use
  • Thalidomide / therapeutic use

Substances

  • Bortezomib
  • Melphalan
  • Thalidomide
  • Pyrazines
  • Dexamethasone